Drug Trial Radar · NCT01275131
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)
Last checked: Nov 20, 2026Latest source record: Jul 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Jan 2011
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- Halozyme TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 12, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if recombinant human hyaluronidase PH20 (rHuPH20) will change the exposure and action of approved insulin analogs when given by continuous subcutaneous insulin infusion (CSII) in participants with Type 1 diabetes mellitus (T1DM). This study is divided into Stage 1, 2, and 3. Stage 3 was started chronologically before Stage 2 and, prior to performing Stage 2, the Sponsor made the decision to terminate Stage 2. Stage 2 was not initiated due to a strategic business decision and termination was not based on safety or efficacy concerns. No participants were enrolled in Stage 2.
Conditions
- Type 1 Diabetes Mellitus
Interventions
Insulin aspartDrug
Recombinant human hyaluronidase PH20 (rHuPH20)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Insulin Exposure (%AUC[0-60]), Stage 1Time frame: 10 minutes predose up to 60 minutes postdose
- Early Exposure to Insulin (%AUC[0-60]), Stage 3Time frame: 10 minutes predose up to 60 minutes postdose on Days 2/7, 3/8, and 5/10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Profil Institute for Clinical Research
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.